Wedbush Starts Ascendis Pharma (ASND) at Outperform

September 26, 2016 6:29 AM EDT
Get Alerts ASND Hot Sheet
Price: $19.01 -2.71%

Rating Summary:
    3 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade ASND Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Wedbush initiates coverage on Ascendis Pharma (NASDAQ: ASND) with a Outperform rating and a price target of $34.00.

Analyst Liana Moussatos commented, "We believe Ascendis' TransCon technology platform creates unique sustained-release (SR) prodrug candidates that reduce treatment burden and regulatory hurdles while retaining composition-of-matter IP. Weekly-dosed TransCon human Growth Hormone (hGH) is the lead candidate in Phase 3 after achieving a best-in-class profile in Phase 2."

She added, "We believe the TransCon platform creates best-in-class candidates and can be applied to many approved drugs. Unlike other sustained-release technologies, TransCon can convert small molecules, peptides and proteins into prodrugs, then release the unmodified approved parent drug for days to months while retaining its approved profile. Less frequent dosing reduces patient burden and the improved compliance also improves real-world efficacy. By qualifying for the FDA 505(b)(2) and EMA bioequivalence pathways clinical and regulatory risks are reduced in our view. In addition, the prodrug is a new chemical entity (NCE) and provides strong intellectual property including composition of matter."

They expect TransCon hGH to be a market leader, a > $1BN market opportunity.

For an analyst ratings summary and ratings history on Ascendis Pharma click here. For more ratings news on Ascendis Pharma click here.

Shares of Ascendis Pharma closed at $19.63 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Hot New Coverage, New Coverage

Related Entities

Liana Moussatos

Add Your Comment